174258-39-0

Usage

Uses

Used in Pharmaceutical Industry:
4-(CHLOROMETHYL)-5-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)OXAZOLE is used as a building block for the synthesis of pharmaceuticals due to its diverse reactivity and potential for incorporation into various structural contexts. Its oxazole ring system may also impart bioactivity, making it of interest for drug discovery and development.
Used in Agrochemical Industry:
In the agrochemical industry, 4-(CHLOROMETHYL)-5-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)OXAZOLE is used as a building block for the synthesis of agrochemicals. Its unique structure and reactivity make it a valuable component in the development of new and effective agrochemical products.
Further research and application of 4-(CHLOROMETHYL)-5-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)OXAZOLE may offer insights into its potential use in chemical and pharmaceutical industries, as well as contribute to the development of innovative solutions in these fields.

Upstream product

• 475480-98-9 4,5-dimethyl-2-(4-trifluoromethylphenyl)-oxazole 3-oxide 
• 455-19-6 4-Trifluoromethylbenzaldehyde 
• 832076-79-6 4,5-dimethyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazole 

Downstream Products

• 125531-55-7 4-{3-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propionyl}-benzaldehyde 
• 1026977-55-8 3-Methoxy-5-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-benzaldehyde 
• 1026286-64-5 3-Fluoro-5-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-benzaldehyde 
• 1025999-65-8 1-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-phenyl}-ethanone 
• 827018-28-0 [4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]-phenyl]sulfonic acid sodium salt 
• 865233-42-7 3-{4-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-phenyl}-hex-4-ynoic acid ethyl ester 
• 475480-99-0 [5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-acetonitrile 
• 403610-55-9 {4-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethylsulfanyl]-2-propyl-phenoxy}-acetic Acid 
• 1026371-01-6 [2-(3-{3-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-phenyl}-undec-2-enyl)-3,5-dioxo-[1,2,4]oxadiazolidin-4-yl]-acetic acid tert-butyl ester 
• 1027038-12-5 C₃₉H₅₁F₃N₂O₇ 
• 1026041-32-6 C₃₇H₄₅F₃N₂O₇ 
• 1028297-69-9 C₃₈H₄₁F₃N₂O₈ 
• 1028303-81-2 C₃₇H₃₈F₄N₂O₇ 
• 1027047-93-3 [2-(3-{3-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-phenyl}-3-phenyl-allyl)-3,5-dioxo-[1,2,4]oxadiazolidin-4-yl]-acetic acid tert-butyl ester 

Relevant academic research and scientific papers

SUBSTITUTED ARYLOXAZOLES AND THEIR USE

The present application relates to novel substituted aryloxazole derivatives, a method for the production thereof, the use thereof for the treatment and/or prophylaxis of diseases and the use thereof for the production of drugs for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.

Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

Design, synthesis, and SAR of novel α-alkoxy-β-arylpropionic acids as potent and balanced PPARαγ coagonists are described. One representative thereof, Aleglitazar ((S)-2Aa), was chosen for clinical development. Its X-ray structure in complex with both receptors as well as its high efficacy in animal models of T2D and dyslipidemia are also presented.

Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders

The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formula [in-line-formulae]Q-L1-P-L2-M-X-L3-A [/in-line-formulae] wherein the definitions of

Structure-based design of indole propionic acids as novel PPARα/γ co-agonists

In the quest for novel PPARα/γ co-agonists as putative drugs for the treatment of type 2 diabetes and dyslipidemia, we have used a structure-based design approach to identify propionic acids with a 1,5-disubstituted indole scaffold as potent PPARα/γ activ

Indolyl derivatives as liver-X-receptor (LXR) modulators

The invention relates to compounds of formula (I): and pharmaceutically acceptable salts and pharmaceutically acceptable esters thereof, wherein R1, R2, R3, R4, R5, R6, A, m, n and p are defined as in claim 1. These compounds can be used as pharmaceutical compositions for the treatment of, for example, diabetes.

A highly regioselective preparation of 4-chloromethyl-5-methyl-2-aryl-1,3- oxazoles

A facile highly regioselective process is described for the formation of 4-chloromethyl-1,3-oxazoles from 1,3-oxazole N-oxide/HCl salts. An explanation is presented for the high regioselectivity in deoxygenation-chlorination using POCl3 with HC

A new approach to the synthesis of 2-aryl-4-halomethyl-5-methyl-1,3- oxazoles by highly regioselective direct halogenation with NBS or NCS/MeCN

A simple and efficient method for the synthesis of 2-aryl-4-bromomethyl-5- methyl-1,3-oxazoles 2 and 2-aryl-4-chloromethyl-5-methyl-1,3-oxazoles 3 is described. The reaction of 2-aryl-4,5-dimethyl-1,3-oxazoles 1 with N-bromosuccinimide and N-chlorosuccini

Oxazole derivatives

The present invention relates to novel oxazole compounds which act as PPARα and PPARγ agonists and are accordingly useful for the treatment of diseases modulated by PPARα and PPARγ such as diabetes.

New azolidinediones as inhibitors of protein tyrosine phosphatase lb with antihyperglycemic properties

Insulin resistance in the liver and peripheral tissues together with a pancreatic cell defect are the common causes of type 2 diabetes. It is now appreciated that insulin resistance can result from a defect in the insulin receptor signaling system, at a site post binding of insulin to its receptor. Protein tyrosine phosphatases (PTPases) have been shown to be negative regulators of the insulin receptor. Inhibiton of PTPases may be an effective method in the treatment of type 2 diabetes. A series of azolidinediones has been prepared as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Several compounds were Potent inhibitors against the recombinant rat and human PTP1B enzymes with submicromolar IC50 values. Elongated spacers between the azolidinedione moiety and the central aromatic portion of the molecule as well as hydrophobic groups at the vicinity of this aromatic region were very important to the inhibitory activity. Oxadiazolidinediones 87 and 88 and the corresponding acetic acid analogues 119 and 120 were the best h-PTP1B inhibitors with IC50 values in the range of 0.12-0.3 μM. Several compounds normalized plasma glucose and insulin levels in the ob/ob and db/db diabetic mouse models.

New azolidinediones and thiadiazolidinediones as antihyperglycemic agents

This invention relates to novel compounds which have demonstrated oral antihyperglycemic activity in diabetic ob/ob and db/db mice, animal models on non-insulin dependent diabetes mellitus (NIDDM ot Type II diabetes). These compounds have the formula: STR1 wherein: R1 is C1 -C6 alkyl, C3 -C8 cycloalkyl, thienyl, furyl, pyridyl, STR2 where R10 is hydrogen, C1 -C6 alkyl, fluorine, chlorine, bromine, iodine, C1 -C6 alkyoxy, trifluoroalkyl or trifluoroalkoxy; R2 is hydrogen or C1 -C6 alkyl; X is O or S; n is 0, 1, or 2; A is STR3 where R3 is hydrogen, C1 -C6 alkyl, halogen, C1 -C6 alkoxy, trifluoroalkyl or trifluoroalkoxy; B is STR4 where R4 is hydrogen, C1 -C6 alkyl, allyl, C6 -C10 aryl, C6 -C10 aryl-(CH2)1-6 --, fluorine, chlorine, bromine, iodine, trimethylsilyl or C3 -C8 cycloalkyl; R5 is hydrogen, C1 -C6 alkyl, C6 -C10 aryl, or C6 -C10 aryl-(CH2)1-6 --; m is 0, 1, or 2; R6 is hydrogen or C1 -C6 alkyl; R7 is hydrogen or C1 -C6 alkyl; R8 and R9 are selected independently from hydrogen, C1 -C6 alkyl, fluorine, chlorine, bromine, or iodine; Y is S; Z is N or CH; or a pharmaceutically acceptable salt thereof.